|
No.
|
Sex
|
Age (years)
|
Pathological
|
Clinicalstage
|
|---|
|
1
|
M
|
54
|
Squamous carcinoma
|
II
|
|
2
|
M
|
49
|
Adenocarcinoma
|
III
|
|
3
|
F
|
64
|
Adenocarcinoma
|
II
|
|
4
|
M
|
63
|
Squamous carcinoma
|
II
|
|
5
|
F
|
52
|
Adenocarcinoma
|
III
|
|
6
|
F
|
68
|
Squamous carcinoma
|
II
|
|
7
|
M
|
66
|
Squamous carcinoma
|
II
|
|
8
|
M
|
72
|
Squamous carcinoma
|
III
|
|
9
|
F
|
70
|
Adenocarcinoma
|
III
|
|
10
|
F
|
69
|
Adenocarcinoma
|
II
|
|
11
|
F
|
57
|
Squamous carcinoma
|
III
|
|
12
|
M
|
73
|
Adenocarcinoma
|
II
|
|
13
|
M
|
59
|
Adenocarcinoma
|
III
|
|
14
|
M
|
49
|
Adenocarcinoma
|
II
|
|
15
|
F
|
72
|
Adenocarcinoma
|
III
|
|
16
|
M
|
68
|
Squamous carcinoma
|
II
|
|
17
|
F
|
76
|
Squamous carcinoma
|
III
|
|
18
|
F
|
48
|
Squamous carcinoma
|
III
|
|
19
|
F
|
72
|
Adenocarcinoma
|
III
|
|
20
|
F
|
68
|
Adenocarcinoma
|
II
|
- Twenty sets of NSCLC and adjacent normal tissues were obtained from the Shanghai Pulmonary Hospital between May 2017 and April 2018. None of the patients had received chemotherapy before sample collection. The clinical stage was determined according to the 8th edition of TNM (UICC and AJCC)
- NSCLC Non-small cell lung cancer, M Male, F Female
